In the United States and other western countries, a form of esophageal and stomach cancer has risen dramatically over the last five decades. Rates of esophageal adenocarcinoma, or EAC, and gastric cardia adenocarcinoma, or GCA, are both highly fatal.
Upstream and CAMP4 target $182M, $67M IPOs
Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled the targeted price ranges for their initial